Excellent info, RW. Thanks, as there are other forums too that are scrambling to learn more.

Just a few points for clarification though ...

We knew that 4 since the reintroduction, and 2 - 3 of the original trial patients, were from the US ... out of the 13 (+ 3 trial) cases we knew about since the reintroduction. That would mean that 6 or 7 of the 16, or about 40% were from the US at that point.

Now we are aware of 24 (+3) = 27, which would be 11 new cases in the last month or so. Have you heard that the majority (and by how much) of the NEW cases are from the EU, or if just all up it is still leaning towards more EU patients?

You mentioned 2 - 3 from major centers in the US ... is that all that is rumored of the new cases to have occurred in the US, or was your point just that 2 - 3 of the cases are from major centers?

Also, since TOUCH is simply a monitoring process, you aren't suggesting that this system could serve to catch the PML before it happens, are you? It may not get as bad with an adequate monitoring program such as TOUCH, but I can't how see a program like that could effectively STOP any cases from occuring.

Thanks again for the summary, and I am really glad to hear the patients are fighting for their rights to understand their risk, just as they did when they wanted this product back on the market.

Cherie